Form 4 for AEON AEON Biopharma, Inc.
Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-14 · accession 0001610717-25-000120 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 2025-05-14 | AEON | Bancroft Robert E. | Pres, CEO, Dir | A - Grant | $0.00 | +177.1K | 177.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-05-14 | A | A | 177,103 | $0.00 | 177,103 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Class A Common Stock for each RSU upon vesting. 25% of the RSUs shall vest on each anniversary of April 29, 2025. |